<?xml version="1.0" encoding="UTF-8"?>
<p id="p0235">Valomaciclovir (EPB-348) is a prodrug that has undergone the preliminary stages of clinical trials for the inhibition of viral DNA polymerase. This ester nucleoside analogue is rapidly converted to omaciclovir (H2G) 
 <italic>in vivo</italic> and subsequently converted by viral enzymes into the phosphorylated form that binds to VZV polymerase. 
 <italic>In vitro</italic> studies have shown its activity against HSV-1 and VZV (
 <xref rid="bib1" ref-type="bibr">Abele et al., 1991</xref>). Valomaciclovir was under phase 2 clinical trials for EBV-infectious mononucleosis (NCT00575185) as well as for the treatment of herpes zoster (NCT00831103).
</p>
